Tiotropium versus salmeterol for the prevention of exacerbations of COPD.


Por: Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM and POET-COPD Investigators

Publicada: 24 mar 2011
Categoría: Medicine (miscellaneous)

Resumen:
Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) but do not specify whether a long-acting anticholinergic drug or a ß(2)-agonist is the preferred agent. We investigated whether the anticholinergic drug tiotropium is superior to the ß(2)-agonist salmeterol in preventing exacerbations of COPD.

Filiaciones:
Vogelmeier C:
 Hospital of the Universities of Giessen and Marburg, Marburg, Germany
ISSN: 00284793





NEW ENGLAND JOURNAL OF MEDICINE
Editorial
MASSACHUSETTS MEDICAL SOC, WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 364 Número: 12
Páginas: 1093-1103
WOS Id: 000288701100004
ID de PubMed: 21428765

MÉTRICAS